Cochrane Abstracts
Rosiglitazone for type 2 diabetes mellitus
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rosiglitazone for Type 2 Diabetes Mellitus." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434693/all/Rosiglitazone_for_type_2_diabetes_mellitus.
Rosiglitazone for type 2 diabetes mellitus. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434693/all/Rosiglitazone_for_type_2_diabetes_mellitus. Accessed January 19, 2025.
Rosiglitazone for type 2 diabetes mellitus. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434693/all/Rosiglitazone_for_type_2_diabetes_mellitus
Rosiglitazone for Type 2 Diabetes Mellitus [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434693/all/Rosiglitazone_for_type_2_diabetes_mellitus.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rosiglitazone for type 2 diabetes mellitus
ID - 434693
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434693/all/Rosiglitazone_for_type_2_diabetes_mellitus
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
